Article By:
Benzinga
Thursday, October 15, 2020 9:15 PM EDT
Opthea, an Australian clinical-stage biotech company, is going public to help fund its Phase 3 trials and take on two large biotech companies.
In this article: OPT Also: BMY, NVS, RHHBY, REGN, TEVA
